

Joshua J Meeks

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/12116809/publications.pdf>

Version: 2024-02-01

126
papers

5,210
citations

81743

39
h-index

95083

68
g-index

127
all docs

127
docs citations

127
times ranked

6835
citing authors

#	ARTICLE	IF	CITATIONS
1	Role of Chromatin Modifying Complexes and Therapeutic Opportunities in Bladder Cancer. <i>Bladder Cancer</i> , 2022, 8, 101-112.	0.2	4
2	Sequential Chemotherapy with Gemcitabine and Docetaxel: Breaking the Chains of bacillus Calmette-GuÃ©rin. <i>Journal of Urology</i> , 2022, 208, 526-527.	0.2	1
3	Cell-free DNA methylation as a predictive biomarker of response to neoadjuvant chemotherapy for patients with muscle-invasive bladder cancer in SWOG S1314.. <i>Journal of Clinical Oncology</i> , 2022, 40, 4506-4506.	0.8	3
4	Editorial Comment. <i>Journal of Urology</i> , 2021, 205, 107-107.	0.2	0
5	Strategies for Bladder Cancer Screening. , 2021, , 45-53.		1
6	Evaluating Patient-Defined Priorities for Female Patients with Bladder Cancer. <i>Bladder Cancer</i> , 2021, 7, 53-60.	0.2	0
7	Rapamycin enhances BCG-specific $\hat{\beta}$ ¹ T cells during intravesical BCG therapy for non-muscle invasive bladder cancer: a randomized, double-blind study. , 2021, 9, e001941.		18
8	Tumor Subtyping: Making Sense of Heterogeneity with a Goal Toward Treatment. <i>Bladder Cancer</i> , 2021, 7, 1-11.	0.2	3
9	Survival by T Stage for Patients with Localized Bladder Cancer: Implications for Future Screening Trials. <i>Bladder Cancer</i> , 2021, 7, 23-31.	0.2	2
10	Subtype-associated epigenomic landscape and 3D genome structure in bladder cancer. <i>Genome Biology</i> , 2021, 22, 105.	3.8	29
11	An integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscle-invasive bladder cancer. <i>Nature Communications</i> , 2021, 12, 2301.	5.8	159
12	100 years of Bacillus Calmetteâ€™GuÃ©rin immunotherapy: from cattle to COVID-19. <i>Nature Reviews Urology</i> , 2021, 18, 611-622.	1.9	80
13	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of urothelial cancer. , 2021, 9, e002552.		16
14	$\hat{\beta}$ ¹ T Cells Support Antigen-Specific $\hat{\beta}$ ² T cellâ€™Mediated Antitumor Responses during BCG Treatment for Bladder Cancer. <i>Cancer Immunology Research</i> , 2021, 9, 1491-1503.	1.6	9
15	Educational Material on Prostate Cancer Screening is Overly Complex and Fails to Meet Recommended Layperson Readability Guidelines. <i>Urology</i> , 2020, 135, 1-3.	0.5	5
16	Willingness to Participate in Home Screening for Urologic Cancers in the General Population: An Online Survey of Over 1400 Adults. <i>Urology</i> , 2020, 136, 35-40.	0.5	0
17	Genomic and Therapeutic Landscape of Non-muscle-invasive Bladder Cancer. <i>Urologic Clinics of North America</i> , 2020, 47, 35-46.	0.8	12
18	Adaptive Immune Resistance to Intravesical BCG in Nonâ€™Muscle Invasive Bladder Cancer: Implications for Prospective BCG-Unresponsive Trials. <i>Clinical Cancer Research</i> , 2020, 26, 882-891.	3.2	98

#	ARTICLE	IF	CITATIONS
19	Reply to Fredrik Liedberg, Pontus Eriksson, and Gottfrid Sjöndahl's Letter to the Editor re: A. Gordon Robertson, Clarice S. Groeneveld, Brian Jordan, et al. Identification of Differential Tumor Subtypes of T1 Bladder Cancer. <i>Eur Urol</i> ;2020:533-7. <i>European Urology</i> , 2020, 78, e230-e231.	0.9	3
20	Identification of Differential Tumor Subtypes of T1 Bladder Cancer. <i>European Urology</i> , 2020, 78, 533-537.	0.9	77
21	MutSignatures: an R package for extraction and analysis of cancer mutational signatures. <i>Scientific Reports</i> , 2020, 10, 18217.	1.6	33
22	Antibody targeting of B7-H4 enhances the immune response in urothelial carcinoma. <i>Oncol Immunology</i> , 2020, 9, 1744897.	2.1	25
23	Genomic heterogeneity in bladder cancer: challenges and possible solutions to improve outcomes. <i>Nature Reviews Urology</i> , 2020, 17, 259-270.	1.9	100
24	Mutation signatures to Pan-Cancer Atlas: Investigation of the genomic landscape of muscle-invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, , .	0.8	5
25	A simplified nomogram to assess risk of bladder cancer in patients with a new diagnosis of microscopic hematuria. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 240-246.	0.8	12
26	Immune Signatures Dominate Molecular Subtyping to Predict Response to Neoadjuvant Immunotherapy. <i>European Urology</i> , 2020, 77, 711-712.	0.9	1
27	INTACT: Phase III randomized trial of concurrent chemoradiotherapy with or without atezolizumab in localized muscle invasive bladder cancer—SWOG/NRG1806. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS586-TPS586.	0.8	6
28	A pilot study of tazemetostat and MK-3475 (pembrolizumab) in advanced urothelial carcinoma (ETCTN) Tj ETQq0 0,0,rgBT /Overlock 10	0.8	8
29	Methodology for in vitro Assessment of Human T Cell Activation and Blockade. <i>Bio-protocol</i> , 2020, 10, e3644.	0.2	0
30	Development of a composite biomarker-based calculator to predict the probability of pathologic complete response (pT0) after neoadjuvant pembrolizumab (pembro) in muscle invasive bladder cancer (MIBC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 539-539.	0.8	0
31	Development of a translational medicine protocol for an NCTN genitourinary clinical trial: Critical steps, common pitfalls and a basic guide to translational clinical research. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 313-317.	0.8	3
32	Limited Upstaging in Luminal Subtype Tumors: Ready for Clinical Practice?. <i>European Urology</i> , 2019, 76, 207-208.	0.9	2
33	Magnetic Resonance Imaging Assessment of Carcinogen-induced Murine Bladder Tumors. <i>Journal of Visualized Experiments</i> , 2019, , .	0.2	2
34	The Cancer Genome Atlas Expression Subtypes Stratify Response to Checkpoint Inhibition in Advanced Urothelial Cancer and Identify a Subset of Patients with High Survival Probability. <i>European Urology</i> , 2019, 75, 961-964.	0.9	141
35	Tumor Location May Predict Adverse Pathology and Survival Following Definitive Treatment for Bladder Cancer: A National Cohort Study. <i>European Urology Oncology</i> , 2019, 2, 304-310.	2.6	18
36	Contemporary Comparison of Open to Robotic Prostatectomy at a Veteran's Affairs Hospital. <i>Military Medicine</i> , 2019, 184, e330-e337.	0.4	7

#	ARTICLE	IF	CITATIONS
37	Molecular footprints of muscle-invasive bladder cancer in smoking and nonsmoking patients. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 818-825.	0.8	21
38	Genomic classification and risk stratification of bladder cancer. <i>World Journal of Urology</i> , 2019, 37, 1751-1757.	1.2	10
39	Disparities in the diagnostic evaluation of microhematuria and implications for the detection of urologic malignancy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 300.e1-300.e7.	0.8	10
40	T1 bladder cancer: current considerations for diagnosis and management. <i>Nature Reviews Urology</i> , 2019, 16, 23-34.	1.9	95
41	A phase III, randomized, open label, multicenter, global study of efficacy and safety of durvalumab in combination with gemcitabine+cisplatin (G+C) for neoadjuvant treatment followed by durvalumab alone for adjuvant treatment in muscle-invasive bladder cancer (MIBC) (NIAGARA).. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS4592-TPS4592.	0.8	6
42	National society-supplied patient materials on prostate cancer screening for the general public: A readability analysis.. <i>Journal of Clinical Oncology</i> , 2019, 37, e23188-e23188.	0.8	0
43	Automated Extraction of Grade, Stage, and Quality Information From Transurethral Resection of Bladder Tumor Pathology Reports Using Natural Language Processing. <i>JCO Precision Oncology</i> , 2019, , 1-6.	1.5	2
44	Clinical Outcome of Retroperitoneal Lymph Node Dissection after Chemotherapy in Patients with Pure Embryonal Carcinoma in the Orchiectomy Specimen. <i>Urology</i> , 2018, 114, 133-138.	0.5	12
45	Rates and Predictors of Conversion to Open Surgery During Minimally Invasive Radical Cystectomy. <i>Journal of Endourology</i> , 2018, 32, 488-494.	1.1	4
46	Discrepancies in staging, treatment, and delays to treatment may explain disparities in bladder cancer outcomes: An update from the National Cancer Data Base (2004-2013). <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 237.e9-237.e17.	0.8	40
47	A Carcinogen-induced mouse model recapitulates the molecular alterations of human muscle invasive bladder cancer. <i>Oncogene</i> , 2018, 37, 1911-1925.	2.6	102
48	Robotic-Assisted vs Laparoscopic Radical Nephrectomy. <i>JAMA - Journal of the American Medical Association</i> , 2018, 319, 1165.	3.8	0
49	Automated Extraction of Grade, Stage, and Quality Information From Transurethral Resection of Bladder Tumor Pathology Reports Using Natural Language Processing. <i>JCO Clinical Cancer Informatics</i> , 2018, 2, 1-8.	1.0	37
50	NCCN Guidelines Insights: Bladder Cancer, Version 5.2018. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 1041-1053.	2.3	171
51	Resetting the epigenetic balance of Polycomb and COMPASS function at enhancers for cancer therapy. <i>Nature Medicine</i> , 2018, 24, 758-769.	15.2	125
52	Editorial Comment. <i>Journal of Urology</i> , 2018, 200, 60-60.	0.2	0
53	Transversus Abdominis Plane Blockade as Part of a Multimodal Postoperative Analgesia Plan in Patients Undergoing Radical Cystectomy. <i>Bladder Cancer</i> , 2018, 4, 161-167.	0.2	26
54	The BBN model: a mouse bladder cancer model featuring basal subtype gene expression and MLL3/MLL4 genetic disruption. <i>Oncoscience</i> , 2018, 5, 172-173.	0.9	12

#	ARTICLE	IF	CITATIONS
55	APOBEC-mediated mutagenesis in urothelial carcinoma is associated with improved survival, mutations in DNA damage response genes, and immune response. <i>Oncotarget</i> , 2018, 9, 4537-4548.	0.8	92
56	Bacillus Calmette-Guérin Manufacturing and SWOG S1602 Intergroup Clinical Trial. <i>Journal of Urology</i> , 2017, 197, 538-540.	0.2	10
57	The evolving genomic landscape of urothelial carcinoma. <i>Nature Reviews Urology</i> , 2017, 14, 215-229.	1.9	89
58	Dipstick Urinalysis as a Test for Microhematuria and Occult Bladder Cancer. <i>Bladder Cancer</i> , 2017, 3, 45-49.	0.2	17
59	The emerging role of homologous recombination repair and PARP inhibitors in genitourinary malignancies. <i>Cancer</i> , 2017, 123, 1912-1924.	2.0	52
60	Multiple Roles for the MLL/COMPASS Family in the Epigenetic Regulation of Gene Expression and in Cancer. <i>Annual Review of Cancer Biology</i> , 2017, 1, 425-446.	2.3	36
61	Extraprostatic Extension Is Extremely Rare for Contemporary Gleason Score 6 Prostate Cancer. <i>European Urology</i> , 2017, 72, 455-460.	0.9	28
62	Bladder Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 1240-1267.	2.3	220
63	Reply by the Authors. <i>Urology</i> , 2017, 110, 267-268.	0.5	0
64	Editorial Comment. <i>Journal of Urology</i> , 2017, 198, 519-519.	0.2	0
65	Molecular Landscape of Non-Muscle Invasive Bladder Cancer. <i>Cancer Cell</i> , 2017, 32, 550-551.	7.7	18
66	Dramatic increase in the utilization of multiparametric magnetic resonance imaging for detection and management of prostate cancer. <i>Abdominal Radiology</i> , 2017, 42, 1255-1258.	1.0	86
67	Treatment of Nonmetastatic Muscle-Invasive Bladder Cancer: American Urological Association/American Society of Clinical Oncology/American Society for Radiation Oncology/Society of Urologic Oncology Clinical Practice Guideline Summary. <i>Journal of Oncology Practice</i> , 2017, 13, 621-625.	2.5	40
68	Genomic characterization of high-risk non-muscle invasive bladder cancer. <i>Oncotarget</i> , 2016, 7, 75176-75184.	0.8	64
69	NCCN Guidelines Insights: Bladder Cancer, Version 2.2016. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 1213-1224.	2.3	93
70	High-Risk of Adverse Pathologic Features in Patients With Clinical T1 High-Grade Bladder Cancer Undergoing Radical Cystectomy. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 1403-1411.	2.3	18
71	The effect of minimally invasive prostatectomy on practice patterns of American urologists. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 255.e1-255.e5.	0.8	65
72	Circulating microRNA signature for the diagnosis of very high-risk prostate cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 10655-10660.	3.3	127

#	ARTICLE	IF	CITATIONS
73	The Evolving Management of Patients With Clinical Stage I Seminoma. <i>Urology</i> , 2016, 98, 113-119.	0.5	14
74	Editorial Comment. <i>Journal of Urology</i> , 2016, 196, 670-671.	0.2	0
75	Do Surgeons or Hospital Economics Ultimately Decide Operative Approach?. <i>JAMA Surgery</i> , 2016, 151, 883.	2.2	0
76	Anti-programmed Death Receptor 1 Blockade Induces Clinical Response in a Patient With Metastatic Collecting Duct Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2016, 14, e431-e434.	0.9	30
77	National comparison of oncologic quality indicators between open and robotic-assisted radical cystectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 431.e9-431.e15.	0.8	21
78	Centralization of Penile Cancer Management in the United States: A Combined Analysis of the American Board of Urology and National Cancer Data Base. <i>Urology</i> , 2016, 90, 82-88.	0.5	33
79	Editorial Comment. <i>Journal of Urology</i> , 2016, 196, 1421-1421.	0.2	0
80	Characteristics of Certifying Urologists Performing Cystectomies in the United States. <i>Urology Practice</i> , 2015, 2, 367-372.	0.2	2
81	Association of the 2011 ACGME Resident Duty Hour Reform with Postoperative Patient Outcomes in Surgical Specialties. <i>Journal of the American College of Surgeons</i> , 2015, 221, 748-757.	0.2	26
82	Emerging therapeutic targets in bladder cancer. <i>Cancer Treatment Reviews</i> , 2015, 41, 170-178.	3.4	108
83	Standard of Care for Small Renal Masses in the 21st Century. <i>JAMA Surgery</i> , 2015, 150, 672.	2.2	7
84	Ambulatory Extended Recovery: Safely Transitioning to Overnight Observation for Minimally Invasive Prostatectomy. <i>Urology Practice</i> , 2015, 2, 121-125.	0.2	4
85	Radical Cystectomy Perioperative Care Redesign. <i>Urology</i> , 2015, 86, 1076-1086.	0.5	17
86	Patterns of Performance of Retroperitoneal Lymph Node Dissections by American Urologists: Most Retroperitoneal Lymph Node Dissections in the United States Are Performed by Low-volume Surgeons. <i>Urology</i> , 2014, 84, 1325-1328.	0.5	21
87	Open Conversion during Minimally Invasive Radical Prostatectomy: Impact on Perioperative Complications and Predictors from National Data. <i>Journal of Urology</i> , 2014, 192, 1657-1662.	0.2	17
88	The Prevalence of Persistent Prostate Cancer after Radiotherapy Detected at Radical Cystoprostatectomy for Bladder Cancer. <i>Journal of Urology</i> , 2014, 191, 1760-1763.	0.2	5
89	Clinical Outcome of Patients with T1 Micropapillary Urothelial Carcinoma of the Bladder. <i>Journal of Urology</i> , 2014, 192, 702-707.	0.2	61
90	Accuracy of post-radiotherapy biopsy before salvage radical prostatectomy. <i>BJU International</i> , 2013, 112, 308-312.	1.3	12

#	ARTICLE	IF	CITATIONS
91	Office-based Management of Nonmuscle Invasive Bladder Cancer. <i>Urologic Clinics of North America</i> , 2013, 40, 473-479.	0.8	8
92	Preoperative Accuracy of Diagnostic Evaluation of the Urachal Mass. <i>Journal of Urology</i> , 2013, 189, 1260-1262.	0.2	33
93	Radical prostatectomy: Positive surgical margins matter. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013, 31, 974-979.	0.8	63
94	Pathological response to neoadjuvant chemotherapy for muscle-invasive micropapillary bladder cancer. <i>BJU International</i> , 2013, 111, E325-30.	1.3	78
95	Clinically Significant Prostate Cancer is Rarely Missed by Ablative Procedures of the Prostate in Men with Prostate Specific Antigen Less Than 4 ng/ml. <i>Journal of Urology</i> , 2013, 189, 111-115.	0.2	8
96	Seminal vesicle involvement at salvage radical prostatectomy. <i>BJU International</i> , 2013, 111, E342-7.	1.3	12
97	A Systematic Review of Neoadjuvant and Adjuvant Chemotherapy for Muscle-invasive Bladder Cancer. <i>European Urology</i> , 2012, 62, 523-533.	0.9	214
98	Environmental toxicology of testicular cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2012, 30, 212-215.	0.8	16
99	Scanometric MicroRNA Array Profiling of Prostate Cancer Markers Using Spherical Nucleic Acid-Gold Nanoparticle Conjugates. <i>Analytical Chemistry</i> , 2012, 84, 4153-4160.	3.2	147
100	Distal urethroplasty for isolated fossa navicularis and meatal strictures. <i>BJU International</i> , 2012, 109, 616-619.	1.3	40
101	Incidence and outcomes of ductal carcinoma of the prostate in the USA: analysis of data from the Surveillance, Epidemiology, and End Results program. <i>BJU International</i> , 2012, 109, 831-834.	1.3	72
102	Urethroplasty for Radiotherapy Induced Bulbomembranous Strictures: A Multi-Institutional Experience. <i>Journal of Urology</i> , 2011, 185, 1761-1765.	0.2	62
103	Genetic Regulation of Prostate Development. <i>Journal of Andrology</i> , 2011, 32, 210-217.	2.0	28
104	Urethroplasty With Abdominal Skin Grafts for Long Segment Urethral Strictures. <i>Journal of Urology</i> , 2010, 183, 1880-1884.	0.2	19
105	Reconstruction of urethral erosion in men with a neurogenic bladder. <i>BJU International</i> , 2009, 103, 378-381.	1.3	10
106	Metastatic Renal Cell Carcinoma With Partial Response to Sunitinib Complicated by Ureteral Obstruction From Necrotic Tumor. <i>Urology</i> , 2009, 73, 444.e11-444.e12.	0.5	2
107	Pediatric Robotic-Assisted Laparoscopic Diverticulectomy. <i>Urology</i> , 2009, 73, 299-301.	0.5	33
108	Impact of Prostate Median Lobe Anatomy on Robotic-assisted Laparoscopic Prostatectomy. <i>Urology</i> , 2009, 73, 323-327.	0.5	44

#	ARTICLE	IF	CITATIONS
109	Application of Continuous Tension to Aid in Performing the Vesicourethral Anastomosis for Robot-Assisted Prostatectomy. <i>Journal of Endourology</i> , 2009, 23, 1941-1944.	1.1	10
110	Stricture Recurrence After Urethroplasty: A Systematic Review. <i>Journal of Urology</i> , 2009, 182, 1266-1270.	0.2	196
111	Staged Reconstruction of Long Segment Urethral Strictures in Men With Previous Pediatric Hypospadias Repair. <i>Journal of Urology</i> , 2009, 181, 685-689.	0.2	54
112	Risk Factors and Management of Urine Leaks After Partial Nephrectomy. <i>Journal of Urology</i> , 2008, 180, 2375-2378.	0.2	109
113	Urethroplasty in Patients With Kidney and Pancreas Transplants. <i>Journal of Urology</i> , 2008, 180, 1417-1420.	0.2	10
114	Delayed Diagnosis of Prostate Cancer With Neuroendocrine Differentiation After Laser TURP. <i>Urology</i> , 2008, 72, 948.e11-948.e12.	0.5	1
115	Percutaneous Endoscopic Management of Persistent Urine Leak after Partial Nephrectomy. <i>Journal of Endourology</i> , 2008, 22, 485-488.	1.1	19
116	Retrieval of Migrated Ureteral Stents by Coaxial Cannulation with a Flexible Ureteroscope and Paired Helical Basket. <i>Journal of Endourology</i> , 2008, 22, 927-930.	1.1	9
117	Full-thickness abdominal skin graft for long-segment urethral stricture reconstruction. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2008, 34, 602-608.	0.7	8
118	Nuclear receptors Sf1 and Dax1 function cooperatively to mediate somatic cell differentiation during testis development. <i>Development (Cambridge)</i> , 2005, 132, 2415-2423.	1.2	81
119	Dax1 is required for testis determination. <i>Nature Genetics</i> , 2003, 34, 32-33.	9.4	168
120	SF1 in the Development of the Adrenal Gland and Gonads. <i>Hormone Research in Paediatrics</i> , 2003, 59, 94-98.	0.8	55
121	Dax1 regulates testis cord organization during gonadal differentiation. <i>Development (Cambridge)</i> , 2003, 130, 1029-1036.	1.2	116
122	Leydig Cell-Specific Expression of DAX1 Improves Fertility of the Dax1-Deficient Mouse ¹ . <i>Biology of Reproduction</i> , 2003, 69, 154-160.	1.2	35
123	Sox3 Is Required for Gonadal Function, but Not Sex Determination, in Males and Females. <i>Molecular and Cellular Biology</i> , 2003, 23, 8084-8091.	1.1	168
124	Genetic Causes of Human Reproductive Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002, 87, 2447-2454.	1.8	70
125	Phenotypic spectrum of mutations in DAX-1 and SF-1. <i>Molecular and Cellular Endocrinology</i> , 2001, 185, 17-25.	1.6	146
126	Mutational Analysis of DAX1 in Patients with Hypogonadotropic Hypogonadism or Pubertal Delay ¹ . <i>Journal of Clinical Endocrinology and Metabolism</i> , 1999, 84, 4497-4500.	1.8	77